Gunderson Dettmer represented client Foresite Capital in its participation of the $135 million Series A financing of Latigo Biotherapeutics, a clinical-stage biotechnology company. Latigo is developing non-opioid pain medicines that target the fundamental mechanism of pain transduction. The new capital will be used to support the continued advancement of Latigo's portfolio of novel pain therapeutics and the growth of the company and its platform.

In the announcement of the transaction, Latigo Biotherapeutics interim CEO Desmond Padhi, Pharm.D. said, "It is particularly gratifying for me to participate in the evolution of Latigo over the past several years since its inception. With a strong syndicate of investors and the significant capital we've raised, we are well positioned to build a company that provides new therapeutic options to patients with pain. Latigo's targets are identified by human genetics, grounded in human biology, and characterized using state-of-the-art human model systems. This combination increases our probability of success across the development continuum."

The Gunderson Dettmer deal team was led by Jonathan Spencer.

Companies
Foresite Capital
Latigo Biotherapeutics